01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
On December 31, 2019, the French government issued decree nº 2019-1590 (the 2019 Decree), together w...
Read More >
Where a business alleges that a former employee stole its confidential information and gave it to a ...
Read More >
On this joint edition of Williams Mullen's Benefits Companion and GovCon Perspectives podcasts, Bryd...
Read More >
Deadlines are approaching for employers to report the year’s employee exercises of incentive stock ...
Read More >
On July 24, 2019, the Chicago City Council passed an expansive fair workweek ordinance, effective Ju...
Read More >
UK employers should proceed with caution when suspending employees, and always consider carefully wh...
Read More >